Genmab A/S (GMAB): Leading Innovation in Antibody Therapeutics
Is the Options Market Predicting a Spike in Genmab (GMAB) Stock?
Genmab Analyst Ratings
H.C. Wainwright Maintains Genmab(GMAB.US) With Buy Rating, Maintains Target Price $50
Genmab's Strong Performance and Strategic Positioning: A Buy Rating With $50 Price Target
Johnson & Johnson Posts Q3 Beat; Lowers Earnings Guidance Amid M&A Impact
Genmab Announces Net Sales of DARZALEX (Daratumumab) for Third Quarter of 2024
Life Science Washington Institute Recognizes ProfoundBio Co-Founders With 2024 Entrepreneurial Achievement Award
TD Cowen Maintains Genmab(GMAB.US) With Hold Rating
Assessing Genmab's Financial Outlook Amidst Darzalex Market Challenges and Patent Expiry Concerns
Genmab A/S (0MGB) Receives a Buy From Barclays
Down -14.68% in 4 Weeks, Here's Why Genmab (GMAB) Looks Ripe for a Turnaround
Redburn Atlantic Initiates Coverage on Genmab With Buy Rating
Genmab A/S Says Baillie Gifford & Co Held The Voting Rights To 3,301,530 Shares In Genmab A/S, Which Amounts To 4.99% Of The Share Capital And Voting Rights As Of October 3, 2024
Major Shareholder Announcement
Genmab A/S Announces Share Capital Expansion
6-K: Report of foreign private issuer (related to financial reporting)
J&J Submits Supplemental BLA for Darzalex Faspro to FDA
Is Genmab A/S (GMAB) One of the Best Revenue Growth Stocks to Buy According to Analysts?
Grant of Restricted Stock Units and Warrants to Employees in Genmab